增长差异化因子15作为肥胖,亚临床动脉样硬化和心力衰竭之间的联系:系统性审查
Raluca-Elena Alexa1,2, Alexandr Ceasovschih1,2, Bianca Codrina Morărașu1,2
1Grigore T. Popa University of Medicine and Pharmacy Iasi, 700115 Iasi, Romania.
Medicina (Kaunas, Lithuania)
|January 28, 2026
概括
增长差异化因子15 (GDF-15) 可能表明肥胖,心力衰竭和动脉样硬化之间的共同途径. 虽然GDF-15显示出预后价值,但需要更多的研究来确认其在心血管风险评估中的临床使用.
科学领域:
- 心血管疾病 心血管疾病
- 代谢障碍 代谢障碍 代谢障碍
- 炎症研究 炎症研究
背景情况:
- 肥胖,心力衰竭和动脉样硬化有共同的炎症和代谢途径,增加心脏代谢风险.
- 增长分化因子15 (GDF-15),一种与炎症和代谢失调相关的细胞因子,与这些共同的途径有关.
- 已确定GDF-15在心血管疾病中的预后价值,新出现的证据表明它在反映亚临床动脉样硬化中的作用.
研究的目的:
- 系统地审查将GDF-15水平与亚临床动脉样硬化标志物的证据.
- 评估GDF-15作为共享心脏代谢途径的综合生物标志物的潜力.
- 评估GDF-15在肥胖和心力衰竭人群风险分层中的实用性.
主要方法:
- 在PROSPERO (CRD420251267457) 登记的PRISMA指南的系统审查.
- 在PubMed,Embase,Scopus和Web of Science中搜索了与GDF-15与亚临床动脉样硬化标志物相关的人类研究.
- 包括18项研究;使用乔安娜·布里格斯研究所工具评估偏见风险;由于异质性而进行叙事合成.
主要成果:
- 大多数研究 (包括18项) 发现GDF-15与动脉样硬化负担增加有关 (例如,内脏介质厚度,冠状动脉分数).
- 在各种人群中观察到关联,包括那些有代谢障碍,炎症疾病和艾滋病毒的人群.
- 结果往往是混的;方法上的局限性 (小样本,横截面设计,成像可变性) 限制了概括.
结论:
- 似乎GDF-15可以整合炎症和代谢压力信号,将肥胖,高血压和亚临床动脉样硬化联系起来.
- 目前的数据支持GDF-15在心血管环境中的预后相关性.
- 需要进一步的研究来证实GDF-15在常规评估和预防性心血管护理中的临床实用性.
更多相关视频
09:20Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
7.0K
05:16Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
Published on: June 10, 2025
560
相关概念视频
01:29Heart Failure II: Pathophysiology
872
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
872
01:17Pathophysiology of Heart Failure
3.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.5K
01:27Heart Failure I: Introduction
847
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
847
01:22Heart Failure VI: Adjunct Therapies
314
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
314
01:22Heart Failure Drugs: Diuretics
948
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
948
01:30Heart Failure V: Medical Management
272
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
272